Q4 2023 Holdings
Filed 2024-02-14 | 42 holdings | $7.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc(APLS) | Common | 03753U106 | $665.1M | 11,111,111 | 9.2% |
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $628.6M | 2,858,888 | 8.7% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $473.0M | 3,755,555 | 6.5% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $469.7M | 1,234,567 | 6.5% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $437.1M | 1,888,888 | 6.0% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $418.9M | 4,344,444 | 5.8% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $414.6M | 4,300,000 | 5.7% |
| Spdr Series Trust - S&P Biotech(XBI) | ETF | 78464A870 | $396.8M | 4,444,444 | 5.5% |
| Amicus Therapeutics Inc(FOLD) | Common | 03152W109 | $388.8M | 27,400,000 | 5.4% |
| Cerevel Therapeutics Hldng(CERE1EUR) | Common | 15678U128 | $320.4M | 7,555,555 | 4.4% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $318.3M | 2,565,555 | 4.4% |
| Mirati Therapeutics Inc(MRTXEUR) | Common | 60468T105 | $287.1M | 4,886,840 | 4.0% |
| Cymabay Therapeutics Inc(CBAYUSD) | Common | 23257D103 | $262.4M | 11,111,111 | 3.6% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $261.0M | 5,666,666 | 3.6% |
| Alnylam Pharmaceuticals Inc(ALNY) | Common | 02043Q107 | $212.7M | 1,111,111 | 2.9% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $161.5M | 2,255,555 | 2.2% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $155.8M | 2,580,000 | 2.2% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $96.1M | 3,775,000 | 1.3% |
| Structure Therapeutics Inc(GPCR) | Sponsored ADR | 86366E106 | $95.1M | 2,333,333 | 1.3% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $91.2M | 4,222,222 | 1.3% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $78.2M | 13,050,000 | 1.1% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $54.5M | 6,700,000 | 0.8% |
| Roivant Sciences LTD(ROIV) | Common | G76279101 | $52.2M | 4,651,162 | 0.7% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $42.9M | 2,980,000 | 0.6% |
| Spyre Therapeutics Inc(SYRE) | Common | 00773J202 | $39.6M | 1,839,138 | 0.5% |
| Karuna Therapeutics Inc | Common | 48576A100 | $39.6M | 125,000 | 0.5% |
| Rocket Pharmaceuticals Inc(RCKT) | Common | 77313F106 | $37.8M | 1,260,900 | 0.5% |
| Arrowhead Pharmaceuticals Inc(ARWR) | Common | 04280A100 | $34.6M | 1,130,000 | 0.5% |
| Marinus Pharmaceuticals Inc(MRNS*) | Common | 56854Q200 | $34.2M | 3,150,000 | 0.5% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $32.8M | 9,000,000 | 0.5% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $31.6M | 785,000 | 0.4% |
| Verrica Pharmaceuticals Inc | Common | 92511W108 | $29.3M | 3,999,999 | 0.4% |
| Immunogen Inc(IMGNEUR) | Common | 45253H101 | $25.9M | 875,000 | 0.4% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $25.6M | 4,535,000 | 0.4% |
| Merus N V | Common | N5749R100 | $24.4M | 888,888 | 0.3% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $22.7M | 868,407 | 0.3% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $22.7M | 2,510,000 | 0.3% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $16.7M | 350,000 | 0.2% |
| Fennec Pharmaceuticals Inc(FENC) | Common | 31447P100 | $13.5M | 1,200,000 | 0.2% |
| Nuvalent Inc(NUVL) | Common | 670703107 | $13.2M | 178,921 | 0.2% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $7.7M | 4,355,555 | 0.1% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $5.8M | 2,849,402 | 0.1% |